Skip to main content

Table 1 Baseline demographic characteristics (prior to leuprolide acetate) of the 120 patients who received Bravelle® and the 118 patients who received Follistim®

From: Highly purified human-derived follicle-stimulating hormone (Bravelle®) has equivalent efficacy to follitropin-beta (Follistim ®) in infertile women undergoing in vitro fertilization

Parameter

Bravelle® (n = 120)

Follistim® (n = 118)

P-value

Age (years)

32.0 ± 3.9

32.5 ± 3.7

0.330

Weight (lbs.)

137.1 ± 21.4

145.8 ± 27.8

0.008

Body mass index (kg/m2)

23.3 ± 3.5

24.5 ± 4.0

0.021

Serum FSH (mIU/mL)

6.3 ± 2.0

6.8 ± 2.1

0.077

Serum LH (mIU/mL)

5.0 ± 2.4

4.6 ± 1.9

0.145

Serum E2 (pg/mL)

43.1 ± 21.4

40.9 ± 20.9

0.420

Primary infertility diagnosis

   

Tubal Factor

50.0

55.9

0.361

Endometriosis

17.5

14.4

0.508

Unexplained

28.3

22.9

0.341

Male factor

4.2

3.4

0.752

Fertility history (%)

   

Full term birth (s)

23.3

31.4

0.087

Abortion(s)/miscarriage(s)

30.8

39.0

0.142

Gonadotropin cycles (excluding IVF/GIFT/PROST)

25.8

25.4

0.889

Previous IVF/GIFT/PROST

27.5

22.9

0.422

  1. Data are means ± SD.